Ace inhibitors versus arbs
Searched over 200M research papers
Summary
10 papers analyzed
Some studies suggest ACE inhibitors and ARBs are equally effective for blood pressure control and reducing kidney and cardiovascular events, while other studies indicate ARBs have a better safety profile and fewer short-term adverse events.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Comparative Effectiveness of ACE Inhibitors and ARBs
Introduction to ACE Inhibitors and ARBs
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are widely used medications for managing hypertension and other cardiovascular conditions. Both drug classes target the renin-angiotensin system but through different mechanisms. ACE inhibitors block the conversion of angiotensin I to angiotensin II, while ARBs block the receptors for angiotensin II. This article synthesizes recent research comparing the effectiveness and safety of these two drug classes.
Blood Pressure Control and Hypertension Management
Equivalence in Blood Pressure Reduction
Multiple studies have consistently shown that ACE inhibitors and ARBs are equally effective in lowering blood pressure in patients with essential hypertension. A systematic review found no significant differences in long-term blood pressure control between the two drug classes . This equivalence makes both options viable for first-line treatment of hypertension.
Safety Profile: Cough and Angioedema
One of the key differences between ACE inhibitors and ARBs lies in their side effect profiles. ACE inhibitors are more likely to cause cough and angioedema compared to ARBs. This has been confirmed by several studies, which found that patients on ACE inhibitors had a higher incidence of these adverse effects . Consequently, ARBs are often preferred for patients who experience these side effects with ACE inhibitors.
Cardiovascular and Kidney Outcomes
Cardiovascular Events and Mortality
In terms of cardiovascular outcomes, both ACE inhibitors and ARBs have been shown to reduce the risk of major cardiovascular events. However, some studies suggest that ACE inhibitors may have a slight edge in reducing all-cause mortality and cardiovascular death, particularly in patients with chronic kidney disease (CKD) . A Bayesian network meta-analysis indicated that ACE inhibitors were more effective than ARBs in reducing the odds of all-cause death in CKD patients.
Kidney Protection
Both ACE inhibitors and ARBs are effective in reducing the progression of kidney disease. However, ACE inhibitors may offer superior protection against kidney failure compared to ARBs. Studies have shown that ACE inhibitors significantly reduce the odds of kidney failure and are possibly more effective than ARBs in this regard .
Special Populations: COVID-19 and Diabetes Prevention
COVID-19 Risk
The use of ACE inhibitors and ARBs during the COVID-19 pandemic has been a topic of concern. A meta-analysis found no significant difference in the risk of severe or lethal COVID-19 between patients using ACE inhibitors or ARBs and those not using these medications . This supports the continued use of these medications during the pandemic, as they do not increase the risk of severe COVID-19 outcomes.
Diabetes Prevention
Both ACE inhibitors and ARBs have been associated with a reduced incidence of new-onset type 2 diabetes. A meta-analysis found that these medications decreased the risk of developing diabetes by approximately 25%. This makes them a valuable option for patients at high risk of diabetes.
Conclusion
In summary, ACE inhibitors and ARBs are both effective in managing hypertension and reducing cardiovascular and kidney disease risks. While they are largely equivalent in terms of blood pressure control, ARBs have a better safety profile with fewer incidences of cough and angioedema. ACE inhibitors may offer superior protection against kidney failure and all-cause mortality, particularly in CKD patients. Both drug classes are safe to use during the COVID-19 pandemic and are effective in preventing new-onset diabetes. Clinicians should consider these factors when choosing between ACE inhibitors and ARBs for individual patients.
Sources and full results
Most relevant research papers on this topic
